On the 19th, Jietai Technology announced a strategic partnership with Eli Lilly to focus on the research and discovery of novel LNP delivery solutions and explore tissue-specific delivery solutions that support various treatment models. This is the first domestic strategic cooperation around LNP delivery with a generative AI platform as the core driver, and the largest AI-driven extra-hepatic LNP delivery platform cooperation in the world, totaling up to 1.1 billion US dollars.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.